$EIGR Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Eiger BioPharmaceuticals, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Eiger BioPharmaceuticals, Inc.. Get notifications about new insider transactions in Eiger BioPharmaceuticals, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 01 2016 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 15.75 | 30,000 | 472,500 | 30,000 | |
| Apr 01 2016 | EIGR | Eiger BioPharmaceu ... | Glenn Jeffrey S | Director | Option Exercise | A | 15.75 | 25,000 | 393,750 | 25,000 | |
| Apr 01 2016 | EIGR | Eiger BioPharmaceu ... | Bramlage Charles | Director | Option Exercise | A | 15.75 | 25,000 | 393,750 | 25,000 | |
| Apr 01 2016 | EIGR | Eiger BioPharmaceu ... | Kjellson Nina S | Director | Option Exercise | A | 15.75 | 25,000 | 393,750 | 25,000 | |
| Mar 28 2016 | EIGR | Eiger BioPharmaceu ... | Cory David A | President and CEO | Option Exercise | A | 15.89 | 285,991 | 4,544,397 | 285,991 | |
| Mar 28 2016 | EIGR | Eiger BioPharmaceu ... | Martins Eduardo Bruno | SVP, Liver and Infe ... | Option Exercise | A | 15.89 | 65,216 | 1,036,282 | 65,216 | |
| Mar 28 2016 | EIGR | Eiger BioPharmaceu ... | Quan Joanne | Chief Medical Offic ... | Option Exercise | A | 15.89 | 53,452 | 849,352 | 53,452 | |
| Mar 28 2016 | EIGR | Eiger BioPharmaceu ... | Shaffer James P | Chief Business Offi ... | Option Exercise | A | 15.89 | 60,699 | 964,507 | 60,699 | |
| Mar 28 2016 | EIGR | Eiger BioPharmaceu ... | WELCH JAMES H | Chief Financial Off ... | Option Exercise | A | 15.89 | 57,571 | 914,803 | 57,571 | |
| Jun 05 2015 | EIGR | Eiger BioPharmaceu ... | NARACHI MICHAEL | Director | Option Exercise | A | 2.16 | 10,000 | 21,600 | 50,000 | |
| Jun 05 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Option Exercise | A | 2.16 | 10,000 | 21,600 | 22,800 | |
| Jun 05 2015 | EIGR | Eiger BioPharmaceu ... | COOPER GRAHAM K | Director | Option Exercise | A | 2.16 | 10,000 | 21,600 | 40,000 | |
| Jun 05 2015 | EIGR | Eiger BioPharmaceu ... | Alton Gregg H | Director | Option Exercise | A | 2.16 | 10,000 | 21,600 | 40,000 | |
| Apr 07 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | M | 8.00 | 6,629 | 53,032 | 645,717 | |
| Apr 07 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | M | 1.12 | 41,302 | 46,258 | 652,346 | |
| Apr 07 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Sell | S | 18.44 | 6,629 | 122,239 | 3,125 | 9.8 K to 3.1 K (-67.96 %) |
| Apr 07 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Sell | S | 18.16 | 41,302 | 750,044 | 9,754 | 51.1 K to 9.8 K (-80.90 %) |
| Apr 07 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Buy | M | 8.00 | 6,629 | 53,032 | 51,056 | 44.4 K to 51.1 K (+14.92 %) |
| Apr 07 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Buy | M | 1.12 | 41,302 | 46,258 | 44,427 | 3.1 K to 44.4 K (+1,321.66 %) |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Option Exercise | M | 8.00 | 1,012 | 8,096 | 150,726 | |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Option Exercise | M | 1.12 | 10,000 | 11,200 | 151,738 | |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Sell | S | 16.95 | 1,012 | 17,153 | 2,895 | 3.9 K to 2.9 K (-25.90 %) |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Sell | S | 17.33 | 10,000 | 173,300 | 3,907 | 13.9 K to 3.9 K (-71.91 %) |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Buy | M | 8.00 | 1,012 | 8,096 | 13,907 | 12.9 K to 13.9 K (+7.85 %) |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Buy | M | 1.12 | 10,000 | 11,200 | 12,895 | 2.9 K to 12.9 K (+345.42 %) |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Option Exercise | M | 1.12 | 4,444 | 4,977 | 139,574 | |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Sell | S | 19.13 | 4,444 | 85,014 | 1,432 | 5.9 K to 1.4 K (-75.63 %) |
| Apr 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Buy | M | 1.12 | 4,444 | 4,977 | 5,876 | 1.4 K to 5.9 K (+310.34 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | M | 8.00 | 6,629 | 53,032 | 693,648 | |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | M | 1.12 | 41,302 | 46,258 | 700,277 | |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Sell | S | 24.71 | 6,629 | 163,803 | 3,125 | 9.8 K to 3.1 K (-67.96 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Sell | S | 24.81 | 41,302 | 1,024,703 | 9,754 | 51.1 K to 9.8 K (-80.90 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Buy | M | 8.00 | 6,629 | 53,032 | 51,056 | 44.4 K to 51.1 K (+14.92 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Buy | M | 1.12 | 41,302 | 46,258 | 44,427 | 3.1 K to 44.4 K (+1,321.66 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Option Exercise | M | 9.58 | 5,000 | 47,900 | 12,800 | |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Option Exercise | M | 11.30 | 2,200 | 24,860 | 17,800 | |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Option Exercise | M | 11.30 | 2,500 | 28,250 | 20,000 | |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Sell | S | 25.00 | 5,000 | 125,000 | 0 | 5 K to 0 (-100.00 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Buy | M | 9.58 | 5,000 | 47,900 | 5,000 | 0 to 5 K |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Sell | S | 22.29 | 2,200 | 49,038 | 0 | 2.2 K to 0 (-100.00 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Sell | S | 22.50 | 2,500 | 56,250 | 2,200 | 4.7 K to 2.2 K (-53.19 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Buy | M | 11.30 | 2,200 | 24,860 | 4,700 | 2.5 K to 4.7 K (+88.00 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Buy | M | 11.30 | 2,500 | 28,250 | 2,500 | 0 to 2.5 K |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Option Exercise | M | 8.00 | 4,000 | 32,000 | 161,738 | |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Option Exercise | M | 1.12 | 10,000 | 11,200 | 165,738 | |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Sell | S | 22.48 | 4,000 | 89,920 | 2,895 | 6.9 K to 2.9 K (-58.01 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Sell | S | 23.29 | 10,000 | 232,900 | 6,895 | 16.9 K to 6.9 K (-59.19 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Buy | M | 8.00 | 4,000 | 32,000 | 16,895 | 12.9 K to 16.9 K (+31.02 %) |
| Mar 09 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Buy | M | 1.12 | 10,000 | 11,200 | 12,895 | 2.9 K to 12.9 K (+345.42 %) |
| Mar 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Option Exercise | M | 1.12 | 7,777 | 8,710 | 144,018 | |
| Mar 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Sell | S | 18.48 | 7,777 | 143,719 | 1,432 | 9.2 K to 1.4 K (-84.45 %) |
| Mar 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Buy | M | 1.12 | 7,777 | 8,710 | 9,209 | 1.4 K to 9.2 K (+543.09 %) |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Option Exercise | M | 8.00 | 4,000 | 32,000 | 175,738 | |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Option Exercise | M | 1.12 | 10,000 | 11,200 | 179,738 | |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Sell | S | 16.08 | 4,000 | 64,320 | 2,895 | 6.9 K to 2.9 K (-58.01 %) |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Sell | S | 16.08 | 10,000 | 160,800 | 6,895 | 16.9 K to 6.9 K (-59.19 %) |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Buy | M | 8.00 | 4,000 | 32,000 | 16,895 | 12.9 K to 16.9 K (+31.02 %) |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Buy | M | 1.12 | 10,000 | 11,200 | 12,895 | 2.9 K to 12.9 K (+345.42 %) |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | M | 8.00 | 6,629 | 53,032 | 741,579 | |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | M | 1.12 | 41,302 | 46,258 | 748,208 | |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Sell | S | 15.94 | 6,629 | 105,666 | 3,125 | 9.8 K to 3.1 K (-67.96 %) |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Sell | S | 15.85 | 41,302 | 654,637 | 9,754 | 51.1 K to 9.8 K (-80.90 %) |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Buy | M | 8.00 | 6,629 | 53,032 | 51,056 | 44.4 K to 51.1 K (+14.92 %) |
| Feb 10 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Buy | M | 1.12 | 41,302 | 46,258 | 44,427 | 3.1 K to 44.4 K (+1,321.66 %) |
| Feb 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Option Exercise | M | 1.12 | 7,777 | 8,710 | 151,795 | |
| Feb 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Sell | S | 16.35 | 7,777 | 127,154 | 1,432 | 9.2 K to 1.4 K (-84.45 %) |
| Feb 03 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Buy | M | 1.12 | 7,777 | 8,710 | 9,209 | 1.4 K to 9.2 K (+543.09 %) |
| Jan 12 2015 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Option Exercise | M | 1.12 | 10,000 | 11,200 | 181,738 | |
| Jan 12 2015 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Sell | S | 18.51 | 10,000 | 185,100 | 1,024 | 11 K to 1 K (-90.71 %) |
| Jan 12 2015 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Buy | M | 1.12 | 10,000 | 11,200 | 11,024 | 1 K to 11 K (+976.56 %) |
| Jan 08 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | M | 1.12 | 41,302 | 46,258 | 789,510 | |
| Jan 08 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Sell | S | 17.51 | 41,302 | 723,198 | 3,125 | 44.4 K to 3.1 K (-92.97 %) |
| Jan 08 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Buy | M | 1.12 | 41,302 | 46,258 | 44,427 | 3.1 K to 44.4 K (+1,321.66 %) |
| Jan 08 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Option Exercise | M | 1.12 | 20,000 | 22,400 | 189,738 | |
| Jan 08 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Sell | S | 17.30 | 20,000 | 346,000 | 2,895 | 22.9 K to 2.9 K (-87.36 %) |
| Jan 08 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Corporate Opera ... | Buy | M | 1.12 | 20,000 | 22,400 | 22,895 | 2.9 K to 22.9 K (+690.85 %) |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | A | 19.53 | 275,000 | 5,370,750 | 830,812 | |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Finance and Adm ... | Option Exercise | A | 19.53 | 80,000 | 1,562,400 | 209,738 | |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | Cleveland Paul B | President and CFO | Option Exercise | A | 19.53 | 140,000 | 2,734,200 | 417,500 | |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Option Exercise | M | 1.12 | 7,777 | 8,710 | 159,572 | |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Option Exercise | A | 19.53 | 72,000 | 1,406,160 | 167,349 | |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Sell | S | 19.88 | 7,777 | 154,607 | 1,432 | 9.2 K to 1.4 K (-84.45 %) |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Buy | M | 1.12 | 7,777 | 8,710 | 9,209 | 1.4 K to 9.2 K (+543.09 %) |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | REED ELIZABETH E | VP, General Counsel | Option Exercise | A | 19.53 | 72,000 | 1,406,160 | 142,500 | |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Option Exercise | A | 19.53 | 80,000 | 1,562,400 | 191,738 | |
| Jan 05 2015 | EIGR | Eiger BioPharmaceu ... | WIKLUND FREDRIK | See Remarks | Option Exercise | A | 19.53 | 80,000 | 1,562,400 | 193,243 | |
| Dec 10 2014 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Option Exercise | M | 1.12 | 41,302 | 46,258 | 555,812 | |
| Dec 10 2014 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Sell | S | 15.00 | 41,302 | 619,530 | 1,531 | 42.8 K to 1.5 K (-96.43 %) |
| Dec 10 2014 | EIGR | Eiger BioPharmaceu ... | ZSEBO KRISZTINA M | Chief Executive Off ... | Buy | M | 1.12 | 41,302 | 46,258 | 42,833 | 1.5 K to 42.8 K (+2,697.71 %) |
| Dec 10 2014 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Option Exercise | M | 1.12 | 10,000 | 11,200 | 111,738 | |
| Dec 10 2014 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Sell | S | 15.00 | 10,000 | 150,000 | 414 | 10.4 K to 414 (-96.02 %) |
| Dec 10 2014 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Buy | M | 1.12 | 10,000 | 11,200 | 10,414 | 414 to 10.4 K (+2,415.46 %) |
| Dec 08 2014 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Finance and Adm ... | Option Exercise | M | 1.12 | 20,000 | 22,400 | 129,738 | |
| Dec 08 2014 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Finance and Adm ... | Sell | S | 12.77 | 20,000 | 255,400 | 691 | 20.7 K to 691 (-96.66 %) |
| Dec 08 2014 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP, Finance and Adm ... | Buy | M | 1.12 | 20,000 | 22,400 | 20,691 | 691 to 20.7 K (+2,894.36 %) |
| Dec 02 2014 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Option Exercise | M | 1.12 | 7,777 | 8,710 | 95,349 | |
| Dec 02 2014 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Sell | S | 12.01 | 7,777 | 93,402 | 577 | 8.4 K to 577 (-93.09 %) |
| Dec 02 2014 | EIGR | Eiger BioPharmaceu ... | TAKEYA RYAN K | VP, Manufacturing | Buy | M | 1.12 | 7,777 | 8,710 | 8,354 | 577 to 8.4 K (+1,347.83 %) |
| Nov 18 2014 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Option Exercise | M | 1.12 | 18,000 | 20,160 | 121,738 | |
| Nov 18 2014 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Sell | S | 11.67 | 18,000 | 210,060 | 0 | 18 K to 0 (-100.00 %) |
| Nov 18 2014 | EIGR | Eiger BioPharmaceu ... | RUDY JEFFREY J | VP, Clinical Operat ... | Buy | M | 1.12 | 18,000 | 20,160 | 18,000 | 0 to 18 K |
| Jun 20 2014 | EIGR | Eiger BioPharmaceu ... | Cleveland Paul B | President and CFO | Option Exercise | A | 14.40 | 277,500 | 3,996,000 | 277,500 | |
| Jun 11 2014 | EIGR | Eiger BioPharmaceu ... | REED ELIZABETH E | VP, General Counsel | Option Exercise | A | 9.12 | 65,000 | 592,800 | 65,000 | |
| May 29 2014 | EIGR | Eiger BioPharmaceu ... | WIKLUND FREDRIK | See Remarks | Option Exercise | A | 9.26 | 10,000 | 92,600 | 10,000 | |
| May 21 2014 | EIGR | Eiger BioPharmaceu ... | COOPER GRAHAM K | Director | Option Exercise | A | 9.58 | 10,000 | 95,800 | 10,000 | |
| May 21 2014 | EIGR | Eiger BioPharmaceu ... | Alton Gregg H | Director | Option Exercise | A | 9.58 | 10,000 | 95,800 | 10,000 | |
| May 21 2014 | EIGR | Eiger BioPharmaceu ... | NARACHI MICHAEL | Director | Option Exercise | A | 9.58 | 10,000 | 95,800 | 10,000 | |
| May 21 2014 | EIGR | Eiger BioPharmaceu ... | Yang Patrick Y | Director | Option Exercise | A | 9.58 | 10,000 | 95,800 | 10,000 | |
| May 21 2014 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Option Exercise | A | 9.58 | 10,000 | 95,800 | 10,000 | |
| May 21 2014 | EIGR | Eiger BioPharmaceu ... | Funder Joshua | Director | Option Exercise | A | 9.58 | 10,000 | 95,800 | 10,000 | |
| Mar 20 2014 | EIGR | Eiger BioPharmaceu ... | LABA REBECQUE J | VP Finance & Admini ... | Option Exercise | A | 12.58 | 10,000 | 125,800 | 10,000 | |
| Mar 04 2014 | EIGR | Eiger BioPharmaceu ... | Yang Patrick Y | Director | Option Exercise | A | 11.30 | 2,500 | 28,250 | 2,500 | |
| Mar 04 2014 | EIGR | Eiger BioPharmaceu ... | Yang Patrick Y | Director | Option Exercise | A | 11.30 | 10,000 | 113,000 | 10,000 | |
| Mar 04 2014 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Option Exercise | A | 11.30 | 2,500 | 28,250 | 2,500 | |
| Mar 04 2014 | EIGR | Eiger BioPharmaceu ... | Honig Peter | Director | Option Exercise | A | 11.30 | 10,000 | 113,000 | 10,000 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Foley Todd | Director | Option Exercise | C | 5.61 | 17,517 | 98,270 | 17,517 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Foley Todd | Director | Option Exercise | C | 0.45 | 218,806 | 98,244 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Foley Todd | Director | Option Exercise | C | 8.00 | 11,370 | 90,960 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Foley Todd | Director | Option Exercise | C | 0.00 | 11,788,047 | 0 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Foley Todd | Director | Buy | P | 8.00 | 111,608 | 892,864 | 1,066,775 | 955.2 K to 1.1 M (+11.68 %) |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Foley Todd | Director | Buy | C | 8.00 | 11,370 | 90,960 | 955,167 | 943.8 K to 955.2 K (+1.20 %) |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Foley Todd | Director | Buy | C | 0.00 | 943,797 | 0 | 943,797 | 0 to 943.8 K |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | WIKLUND FREDRIK | VP Corp Dvlpmnt & I ... | Buy | P | 8.00 | 20,000 | 160,000 | 20,000 | 0 to 20 K |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | PFIZER INC | 10% Owner | Option Exercise | C | 5.61 | 42,659 | 239,317 | 42,659 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | PFIZER INC | 10% Owner | Option Exercise | C | 0.45 | 532,818 | 239,235 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | PFIZER INC | 10% Owner | Option Exercise | C | 8.00 | 23,145 | 185,160 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | PFIZER INC | 10% Owner | Option Exercise | C | 0.00 | 19,289,531 | 0 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | PFIZER INC | 10% Owner | Buy | P | 8.00 | 227,261 | 1,818,088 | 1,794,803 | 1.6 M to 1.8 M (+14.50 %) |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | PFIZER INC | 10% Owner | Buy | C | 8.00 | 23,145 | 185,160 | 1,567,542 | 1.5 M to 1.6 M (+1.50 %) |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | PFIZER INC | 10% Owner | Buy | C | 0.00 | 1,544,397 | 0 | 1,544,397 | 0 to 1.5 M |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 5.61 | 25,481 | 142,948 | 25,481 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.45 | 318,266 | 142,901 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 8.00 | 16,537 | 132,296 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Novartis Bioventures Ltd | 10% Owner | Option Exercise | C | 0.00 | 17,146,250 | 0 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Novartis Bioventures Ltd | 10% Owner | Buy | P | 8.00 | 162,386 | 1,299,088 | 1,551,721 | 1.4 M to 1.6 M (+11.69 %) |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 8.00 | 16,537 | 132,296 | 1,389,335 | 1.4 M to 1.4 M (+1.20 %) |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Novartis Bioventures Ltd | 10% Owner | Buy | C | 0.00 | 1,372,798 | 0 | 1,372,798 | 0 to 1.4 M |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | NARACHI MICHAEL | Director | Buy | P | 8.00 | 62,500 | 500,000 | 62,500 | 0 to 62.5 K |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Lundbeckfond Invest A/S | 10% Owner | Option Exercise | C | 5.61 | 28,666 | 160,816 | 28,666 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Lundbeckfond Invest A/S | 10% Owner | Option Exercise | C | 0.45 | 358,049 | 160,764 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Lundbeckfond Invest A/S | 10% Owner | Option Exercise | C | 8.00 | 18,605 | 148,840 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Lundbeckfond Invest A/S | 10% Owner | Option Exercise | C | 0.00 | 19,289,531 | 0 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Lundbeckfond Invest A/S | 10% Owner | Buy | P | 8.00 | 182,681 | 1,461,448 | 1,745,683 | 1.6 M to 1.7 M (+11.69 %) |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Lundbeckfond Invest A/S | 10% Owner | Buy | C | 8.00 | 18,605 | 148,840 | 1,563,002 | 1.5 M to 1.6 M (+1.20 %) |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Lundbeckfond Invest A/S | 10% Owner | Buy | C | 0.00 | 1,544,397 | 0 | 1,544,397 | 0 to 1.5 M |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Kordel Johan | Director | Option Exercise | C | 5.61 | 28,666 | 160,816 | 28,666 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Kordel Johan | Director | Option Exercise | C | 0.45 | 358,049 | 160,764 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Kordel Johan | Director | Option Exercise | C | 8.00 | 18,605 | 148,840 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Kordel Johan | Director | Option Exercise | C | 0.00 | 19,289,531 | 0 | 0 | |
| Feb 06 2014 | EIGR | Eiger BioPharmaceu ... | Kordel Johan | Director | Buy | P | 8.00 | 182,681 | 1,461,448 | 1,745,683 | 1.6 M to 1.7 M (+11.69 %) |